tbuckley/cabot-search huggingface dataset:
120P Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Authors: None A.Lebeaud, L. Antoun, J-R. Paccard, J. Edeline, N. Fares, C. Tournigand, T. Lecomte, D. Tougeron, V. Hautefeuille, A. Vienot, J. Henriques, N. Williet, J-B. Bachet, C. Smolenschi, A. Hollebecque, D. Malka, C. Neuzillet, D. Vernerey, A. Boileve, A. Turpin
Journal: Annals of Oncology (2023)
CN15 Real-life clinical and organizational evaluation of telemonitoring and assisted telemonitoring in more than 1500 cancer patients
Authors: S. Martin, A. Fritsch, C. Jouannaud, J. Martin-Babau, B. Mennecier, F. Slimano, A. Bordeau, L. Guéroult-Accolas, B. Delcour, E. Raymond, S. Renet, C. Sonntag, A. Morel, P. Barthelemy
Journal: Annals of Oncology (2023)
2314P Quality and safety of research biopsies (RB) in oncology clinical trials
Authors: P.G. Nuciforo, F. Ruiz-Pace, J. Jimenez, R. Comas, R. Fasani, C. Viaplana, C. Sevillano, P. Martinez, X. Serres Créixams, C. Saura Manich, M.E. Elez Fernandez, A. Oaknin, I. Braña, E. Muñoz Couselo, T. Macarulla, J. Carles Galceran, J. Tabernero, E. Felip, E. Garralda, R. Dienstmann
Journal: Annals of Oncology (2023)
121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Authors: B. Delaunay, A. Hollebecque, M. Bouattour, J.F. Blanc, E. Assenat, A. Turpin, M. Sarabi, G. Roth, D. Tougeron, J. Edeline, M. Ben Abdelghani, A. Vienne, S. Hiret, P. Artru, M. Stacoffe, D. Malka, C. Neuzillet, A. Lievre, R. Guimbaud, N. Fares
Journal: Annals of Oncology (2023)
2313P APOBEC mutagenesis and macrophage infiltration in cancer
Authors: A. Gazzo, A. Marra, Y. Zhu, A. Gupta, P. Selenica, X. Pei, B. Weigelt, F. Pareja, N. Riaz, J.S. Reis-Filho, S. Chandarlapaty
Journal: Annals of Oncology (2023)
2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate
Authors: Á. Quintanal-Villalonga, S. Zaidi, W.R. Karthaus, Y.A. Zhan, M. Shafer, J. Qiu, E. de Stanchina, M.C. Haffner, C.L. Sawyers, C.M. Rudin
Journal: Annals of Oncology (2023)
1535P Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Authors: M. Scheck, T.O. Goetze, T.J. Ettrich, H. Schmalenberg, M.R. Clemens, R.J.C. Mahlberg, S. Heeg, S. Kanzler, G. Hapke, P.C. Thuss-Patience, A. Kestler, A. Treschl, G.A. Frost, S. Heidel, M. Schiemer, S. Junge, C. Pauligk, S-E. Al-Batran, S. Lorenzen
Journal: Annals of Oncology (2023)
2238P Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Authors: J.M. Piulats Rodriguez, E. Guc, A. Treveil, P. Nieto, A. Camera, J. Clubley, H. Heyn, S. Stanhope, L. Collins, K. Ranade, A. Benlahrech
Journal: Annals of Oncology (2023)
1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
Authors: K. Muro, H. Kawakami, S. Kadowaki, A. Makiyama, M. Tsuda, K. Hirata, N. Sugimoto, N. Machida, H. Hara, H. Hirano, T. Esaki, Y. Komatsu, S. Hironaka
Journal: Annals of Oncology (2023)
31P Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Authors: S. Calfa, A.J.A. de Freitas, T.T. Komoto, C.R. Nunes, J.C.P. Resende, R. dos Reis, R.M. Reis, M.M.C. Marques
Journal: Annals of Oncology (2023)
1537P A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Authors: D. Takahari, H. Shoji, A. Ooki, H. Hirano, N.T. Okita, K. Nagashima, J. Adachi, K. Yamaguchi, K. Kato, N. Boku
Journal: Annals of Oncology (2023)
2244P Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Authors: V. Quagliariello, M. Passariello, A. Di Mauro, I. Bisceglia, A. Paccone, M. Iovine, F. Bruzzese, G. Palma, F. Florio, A. Luciano, N. Maurea
Journal: Annals of Oncology (2023)
3O IGSF8 is an innate immune checkpoint and cancer immunotherapy target
Authors: K. Benhadji, Y. Li, X. Wu, H. Liu, X. Xiao, H. Liu, Q. Ding, B. Xie, C. Sheng, R. Zheng, Q. Yu, X. Hu, X.S. Liu, T. Xiao
Journal: Annals of Oncology (2023)
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
Authors: G. Mazzaschi, M. Dos Santos, P. Bergeron, L. Sitterle, M. Gérbé de Thoré, W. Liu, C. Clémenson, L. Meziani, O. Bawa, A. Leroy, R. Sun, L. Moron Dalla Tor, F. Quaini, M. Tiseo, F. Milliat, C. Robert, M. Mondini, E. Deutsch
Journal: Annals of Oncology (2023)
1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Authors: K-W. Lee, L-Y. Bai, M. Jung, J. Ying, Y-H. Im, D-Y. Oh, J.Y. Cho, S.C. Oh, Y. Chao, P. Zhou, Y. Bao, Y-K. Kang
Journal: Annals of Oncology (2023)
1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
Authors: B. Li, J. Zhang, M. Li, K. Zhang, A. Zheng, G. Li, W. Huang, S. Chen, X. Li, X. Chen, Y. Sheng, X. Sun, L. Liu, X. Liu, J. Li, J. Wang, H. Ge, S. Ye, Q. Pang
Journal: Annals of Oncology (2023)
2306P How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Authors: E.D. Chiru, C. Grasic Kuhar, A. Oseledchyk, A. Schötzau, S. Ebner, C. Kurzeder, M.H.F. Vetter
Journal: Annals of Oncology (2023)
1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Authors: M.D. Isla Casado, E. Arriola, M.R. García-Campelo, P. Diz Tain, C. Marti Blanco, M.M. Lopez-Brea Piqueras, A.L. Moreno Vega, L.A. Leon Mateos, J.M. Oramas Rodriguez, V. Gutierrez Calderon, M. Majem, A. Sanchez Hernandez, C. Aguado, R. Alvarez Cabellos, J.L. Marti Ciriquian, A. Moreno Paul, J.L. Firvida Perez, Á. Callejo Mellén, L. Baez, L. Paz-Ares
Journal: Annals of Oncology (2023)
2011P Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Authors: P. Jain, C. Barrera, S. Perimbeti, V.S. Viswanathan, B. Beshai, M. Khorrami, A. Madabhushi
Journal: Annals of Oncology (2023)
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Authors: J. Mazieres, M. Duruisseaux, H. Curcio, C. Morizane, R. Galot, S. Rottey, J.A. Stratmann, Y. Ma, M. Bouzaggou, L. Geng, M. Wermke
Journal: Annals of Oncology (2023)
2325P Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Authors: R. Rosell, A. Jain, J. Codony-Servat, C. Shivamallu, S.P. Kollur, A. Prasad, P. Vishwanath, E. Jantus Lewintre, M. Ito, A.F. Cardona Zorrilla, O.G. Arrieta Rodriguez, C. Pedraz-Valdunciel, J. González Nieto, A. Aguilar, M.A. Molina-Vila, M. Gonzalez Cao
Journal: Annals of Oncology (2023)
2349P Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Authors: H. Bani Hani, H. Abu-Fares, S. Abdel-Razeq, B.S. Sharaf, H. Abu-Jaish, I. Hamad, Z. Zeidan, M. Horani, A. Abd Elqader, S. Mahafdah, S. Young, B. Heald, H. Abdel-Razeq
Journal: Annals of Oncology (2023)
2253P RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Authors: H. Adderley, W. McDaid, J. Searle, L. Wilson, A. Marinello, M. Aldea, J. Aredo, H. Wakelee, B. Besse, A. Malliri, C.R. Lindsay
Journal: Annals of Oncology (2023)
2248P Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Authors: S. Tamberi, G. Marisi, C. Molinari, E. Grassi, E. Petracci, D. Angeli, A. Virga, I. Banchelli, C. Zingaretti, F. Pietrantonio, F. Gelsomino, I. Carandina, M. Banzi, A. Bonetti, G.L. Frassineti, G. Ugolini, S. Santucci, J. Longobardi, P. Ulivi
Journal: Annals of Oncology (2023)
2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Authors: A. Marinello, M.R. Ghigna, None F.G. Dall'Olio, M. Mandarano, A. Russo, J. Raimbourg, S. Terrisse, G. Metro, A. Gazzah, F. Barlesi, J. Remon Masip, D. Planchard, B. Besse, M. Aldea
Journal: Annals of Oncology (2023)
2003P Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Authors: A. Bruni, F. Bertolini, P. Borghetti, V. Scotti, M. Sepulcri, G. Pasello, N. Giaj-Levra, S. Grisanti, M. Katica, A. Cappelli, P. Garlatti, G. Guaitoli, M. Dominici, F. Lohr
Journal: Annals of Oncology (2023)
130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Authors: B. Garmezy, M. Borad, C-C. Lin, L-T. Chen, C.A. Perez, S. Kato, B. Tam, P. Severson, C.S. Quah, J.J. Harding
Journal: Annals of Oncology (2023)
42P Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Authors: B. Serambeque, S. Ferreira, M. Piñeiro, S. Lopes, B. Costa, N.A. Pereira, C.M. Marto, M.F. Botelho, M.J. Carvalho, T. Pinho e Melo, M. Laranjo
Journal: Annals of Oncology (2023)
2236P MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Authors: B. Shum, I. Lobon, T. Lesluyes, H. Pallikonda, L.T. Khoja, P. Kissoonsingh, S.H. Nahm, S. El Badri, E. Peleva, A. Fusi, A.C. Gault, R. Marais, N. Dhomen, P. Arumugam, L.M. Pickering, S. Danson, J. Larkin, K.R. Litchfield, P. Lorigan, S. Turajlic
Journal: Annals of Oncology (2023)
1998P Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy (TRACES): Updated results from TRACES
Authors: Y. Liu, L. Wu, D. Huang, Q. Wang, Y. Fan, Z. Liu, H. Fan, W. Yao, B. Liu, G. Yu, Y. Pan, F. Xu, Z. He, X. Dong, R. Ma, X. Min, X. Ge, H. Chen, Q. Liu, Y. Cheng
Journal: Annals of Oncology (2023)
2007P Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Authors: E. Panagiotou, M.E. Livanou, A. Montgomery, M. Mastrogeorgiou, C. Moeckel, N. Syrigos, I. Mouratidis, A. Charpidou, I. Georgakopoulos-Soares, I. Vathiotis
Journal: Annals of Oncology (2023)
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Authors: Yelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yanez, Lucjan S Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shu-Kui Qin, Eric Van Cutsem, Josep Tabernero, Kan Li, Chie-Schin Shih, Pooja Bhagia, Sun Young Rha
Journal: The Lancet (2023)
1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin
Authors: N.A.D. Guchelaar, B.J. Noordman, M. Welten, M. van Santen, M.J. de Neijs, S.L. Koolen, R.H.A. Verhoeven, E. Oomen-de Hoop, H.W.M. van Laarhoven, I.H.J.T. de Hingh, G-J. Creemers, B. Mostert, B.P.L. Wijnhoven, R.H. Mathijssen
Journal: Annals of Oncology (2023)
1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study
Authors: A. Calles Blanco, A.F. Navarro Mendivil, B. Doger de Spéville, E. Álvarez Colomé, M.J. De Miguel Luken, R.M. Alvarez, V. Moreno Garcia, None J. ramon, M. Arregui Valles, E. Corral de la Fuente, D. Alcalá, M. Fernández, J. Rodríguez Morató, E. Calvo, R. Palmero Sanchez, M. Jové, E. Felip
Journal: Annals of Oncology (2023)
CN42 A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial
Authors: C. Bandiera, E. Cardoso, I. Locatelli, K. Zaman, A. Diciolla, A. Digklia, A. Stravodimou, V. Cristina, V. Aedo-Lopez, A.M. Dolcan, A. Sarivalasis, H. Bouchaab, J. Pasquier, J. Dotta-Celio, S. Peters, A.D. Wagner, C. Csajka, M.P. Schneider
Journal: Annals of Oncology (2023)
1546P Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Authors: H. Hirano, A. Kawazoe, K. Yamaguchi, T. Hamaguchi, Y. Narita, S. Boku, T. Oshima, H. Hara, Y. Hamamoto, T. Esaki, K. Ishido
Journal: Annals of Oncology (2023)
2018P Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Authors: J. Zhao, W. Li, X. Zhang, Y. Du, Y. Zhang, Y. Zhang, R. Shi, Y. Zhang, F. Su, Y. Zhang, W. Fan, W. Hu, Y. Wang
Journal: Annals of Oncology (2023)
40P Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Authors: I. Moreno Candilejo, L. Paniagua Herranz, B. Doger de Spéville, C. Diaz-Tejeiro, C. Nieto-Jimenez, A. Sanvicente, J. Ramon, V. Moreno Garcia, E. Calvo, A. Ocana Fernandez
Journal: Annals of Oncology (2023)
2232O Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031
Authors: N. Harbeck, C. Duan, K. DuPree, C-W. Chang, C.H. Barrios, H.A. Zhang, S. Saji, K.H. Jung, M.L. Telli, M. Liste Hermoso, S. Chui, M. Dieterich, E.A. Mittendorf, L. Molinero
Journal: Annals of Oncology (2023)
1515P Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Authors: A. Gordon, C.Y.K. Fong, M. Davidson, S. Cromarty, S. Kidd, K. Piadel, C. Peckitt, L. Satchwell, Z. Rajan, R. Begum, O. Zhitkov, P. Das, S. Sothi, R.A. Herbertson, S. Darby, T.S. Waddell, A. Bradshaw, N. Starling, I. Chau, D. Cunningham
Journal: Annals of Oncology (2023)
2021P Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Authors: G. Pasello, G. Pigato, M. Lorenzi, M.V. Resi, L. Urso, S. Giunco, A. Ferro, A. Dal Maso, S. Frega, L. Bonanno, A. De Rossi, V. Ciminale, S. Indraccolo, V. Guarneri
Journal: Annals of Oncology (2023)
108P FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Authors: B. Zheng-Lin, D. Walden, J. Larson, S. McDonnell, J. Frank, P. Raman, C. Eslinger, B. Ueberroth, F-S. Ou, N. Larson, M.B. Sonbol, C. Wu, N. Tran, H. Babiker, M. Borad, L. Roberts, D. Ahn, T. Bekaii-Saab
Journal: Annals of Oncology (2023)
1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial
Authors: A. Dowlati, A. Cervantes, S. Babu, E.P. Hamilton, S.F. Wong, A. Tazbirkova, I.G. Sullivan, C. Van Marcke de Lummen, A. Italiano, J. Patel, S. Mekan, T. Wu, A.C. Chiang
Journal: Annals of Oncology (2023)
2246P Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Authors: E. Segui Solis, E. Sanfeliu Torres, B. Gonzalez-Farre, T. Pascual, F. Brasó-Maristany, P. Galván, X. González Farre, F. Salvador, E. Felip, E. Garralda, L. Paz-Ares, M. Juan, R. Mesia Nin, A.M. Arance Fernandez, A. Cervantes, J. Martin-Liberal, G. Villacampa Javierre, J. Tabernero, A. Prat
Journal: Annals of Oncology (2023)
1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
Authors: M. Sachdeva, J.J. Zhao, K.X. Zhu, D. Ting Wei Yap, N. Zhun Hong Wong, N.K. Barr, R. Sundar
Journal: Annals of Oncology (2023)
2258P Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Authors: L.P. Smabers, E. Wensink, C.S. Verissimo, E. Koedoot, M. Doorn, K-C. Pitsa, M. Huismans, C. Higuera Barón, L. Valkenburg-van Iersel, A. Brousali, R. Overmeer, M. Braat, S. Elias, R. Vries, O. Kranenburg, M. Koopman, S. Boj, J.M.L. Roodhart
Journal: Annals of Oncology (2023)
2O PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells with implications for cancer immunotherapy
Authors: Y. Wu, D. Davies, S. Kamdar, R. Woolf, I. Zlatareva, M.L. Iannito, C. Morton, Y. Haque, H. Martin, O. O'Neill, O. Nussbaumer, A. Hayday
Journal: Annals of Oncology (2023)
2260P Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Authors: A. Paccone, M. Iovine, M. Scherillo, F. Florio, F. Russo, I. Bisceglia, F. Maurea, V. Giordano, N. Maurea, V. Quagliariello
Journal: Annals of Oncology (2023)
1577P Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response
Authors: C.G. Kim, J-Y. Koh, S-J. Shin, J-H. Shin, M. Hong, H.C. Chung, S.Y. Rha, H.S. Kim, C-K. Lee, H. Kim, J.H. Kim, S. Lee, S.K. Park, H. Kim, S. Park, J.Y. Ahn, H.C. Jeung, J.S. Lee, Y-D. Nam, M. Jung
Journal: Annals of Oncology (2023)
2328P Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Authors: F. Pareja, H. Dopeso, Y.K. Wang, A. Gazzo, D. Brown, P. Selenica, J. Bernhard, J. Sue, M.C.H. Lee, R. Godrich, A. Casson, B. Weigelt, M. Hanna, J.D. Kunz, B. Rothrock, C. Kanan, G.J. Oakley, D. Klimstra, T. Fuchs, J.S. Reis-Filho
Journal: Annals of Oncology (2023)
2249P Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Authors: K. Crame, G. Longinotti, M. Catarinella, P. Prinz, S. Tippmer, K. Mutze, A. Coluccio, M. Salvermoser, J. Bittmann, M. Bürdek, B. Lösch, C. Geiger, K. Davari, D.J. Schendel
Journal: Annals of Oncology (2023)
109P DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Authors: I. Mavroeidi, T. Reissig, S. Kalbourtzis, S-T. Liffers, T. Herold, S. Kasper-Virchow, H-U. Schildhaus, M.H.H. Schuler, J. Siveke
Journal: Annals of Oncology (2023)
100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)
Authors: S.L. Chan, R.S. Finn, J.W. Valle, R.K. Kelley, C. Yoo, J. Furuse, Z. Ren, T. Yau, H.J. Klumpen, M. Ozaka, C. Verslype, M. Bouattour, J.O. Park, J. Edeline, M. Ueno, A. Vogel, L. Yu, U. Malhotra, A.B. Siegel, S. Qin
Journal: Annals of Oncology (2023)
1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)
Authors: T. Wakatsuki, D. Takahari, N. Yamamoto, A. Ooki, K. Chin, N. Kurihara, T. Mashima, M. Ogura, I. Nakayama, S. Fukuoka, H. Hirano, K. Minashi, H. Hara, K. Kato, N. Ishizuka, S. Kitano, H. Seimiya, K. Takeuchi, N. Boku, K. Yamaguchi
Journal: Annals of Oncology (2023)
1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Authors: M.R. García-Campelo, M. Dómine, J. de Castro Carpeño, A.L. Moreno Vega, S. Ponce Aix, E. Arriola, E. Carcereny, M. Majem, G. Huidobro Vence, E. Esteban Gonzalez, J. Fuentes Pradera, A.L.O. Ortega Granados, M. Guillot Morales, B. Massuti Sureda, P. Lianes Barragan, R. Alonso Calderon, C.A. Fajardo, L. Crama, N. Lerones Laborda, M. Cobo Dols
Journal: Annals of Oncology (2023)
101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Authors: H.S. Wasan, J.J. Harding, J. Fan, D-Y. Oh, H.J. Choi, J.W. Kim, H-M. Chang, L. Bao, H. Sun, T. Macarulla, F. Xie, J-P. Metges, J. Ying, J.A. Bridgewater, M. Tejani, E.Y. Chen, M.P. Ducreux, J. Ma, P. Garfin, S. Pant
Journal: Annals of Oncology (2023)
1581P Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Authors: M.V. Sedova, M.A. Batov, A.A. Kolomeytseva, V.M. Khomyakov, N.N. Volchenko, A.A. Fedenko, A.D. Kaprin
Journal: Annals of Oncology (2023)
2318P Value of broad molecular profiling for cancer diagnosis
Authors: L.V.A. Werstein, C.E. Heilig, M-V. Teleanu, J. Hüllein, M. Singh, S. Bauer, T. Kindler, F. Klauschen, C.H. Brandts, D.T. Rieke, L. Illert, M. Börries, S. Kreutzfeldt, P. Horak, D. Hübschmann, D.B. Lipka, H. Glimm, W. Hartmann, S. Fröhling
Journal: Annals of Oncology (2023)
2308P CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Authors: B. Janji, M. Zaeem Noman, J. Hossain, L. Prestegarden, C. Pico-Navarro, E. Rigg, M. Bosseler, R. Bjerkvig
Journal: Annals of Oncology (2023)
45P Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Authors: S. Rao, Y. Fu, M. Zhang, L. Qin, S. Bavadekar, H. Cui, C. Xu, S. Chen, C. Yang, X. Xiang, L. Liu, L. Diao, S. Yan, X. Wang, F. Ren
Journal: Annals of Oncology (2023)
2024P Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Authors: M. Dómine, B. García San Andres, J. Gómez, J. Iglesias, B. Citoler, M. Prades
Journal: Annals of Oncology (2023)
1996P The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Authors: C. Browne, T. Ayoube, N. Samarasinghe, S.K. Hussaini, A. Warner, M. Black, D.A. Palma, J. Raphael, M.S. Kuruvilla, P. Blanchette
Journal: Annals of Oncology (2023)
1524P First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Authors: L. Shen, D. Liu, N. Li, W. Guo, T. Liu, L. Zhang, X. Zhu, C. Qi, L. Xu, X. Qian, C. Germa
Journal: Annals of Oncology (2023)
357P Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Authors: P.T. Nguyen, S. Momtahen, M. Momtahen, P. Atwal, W.W. Yap, B. Bradshaw, A. Chinnadurai, H.M. Abusin, A. Gurjal, S. Gilmour, M.A. Shaikh, R. Ramaseshan, F. Golnaraghi, J. Ko
Journal: Annals of Oncology (2023)